Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Luca Gianni(Fondazione Michelangelo), Gianni Bonadonna(Hospital Clínico Universitario de Valencia), Aňa Lluch(Hospital Clínico Universitario de Valencia), Antonio Llombart‐Cussac(MedSIR (Spain)), Milvia Zambetti(Hospital Clínico Universitario de Valencia), Ángel Martínez-Agulló(Hospital Clínico Universitario de Valencia), Pinuccia Valagussa(Fondazione Michelangelo), Semiglazov Vf(Institute of Oncology NN Petrov), Günther Raab(Hospital Clínico Universitario de Valencia), А. А. Божок(Hospital Clínico Universitario de Valencia), V. Guillem Porta(Fundación Instituto Valenciano de Oncología), Dolores Sabadell(Hospital Clínico Universitario de Valencia), Juan José López Gómez(Hospital Clínico Universitario de Valencia), Marco Greco(Hospital Clínico Universitario de Valencia), Mauro Mansutti(Hospital Clínico Universitario de Valencia), Mikhail Byakhov(Hospital Clínico Universitario de Valencia), W. Eiermann(Ludwig-Maximilians-Universität München), José Baselga(Harvard University)
Cited by 165
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k